CADM2 antibodies are widely used in:
Glioma: CADM2 overexpression inhibits proliferation (57.6% reduction in U87 cells) and metastasis by downregulating β-catenin and upregulating E-cadherin .
Colorectal Cancer: Low CADM2 correlates with advanced tumor stage and poor survival (HR = 2.1, p < 0.001) .
Lung Cancer: Silencing CADM2 enhances EMT, increasing brain metastasis risk (OR = 3.2) .
Cell Cycle Regulation: Reduces cyclin D1 and CDK4/2 expression, arresting G1/S transition .
EMT Modulation: Suppresses vimentin and Slug while enhancing E-cadherin in HCC and NSCLC .
Biomarker Potential: CADM2 expression predicts survival in glioma (median OS: 22 vs. 14 months, high vs. low) and CRC (AUC = 0.84) .
Therapeutic Target: Restoring CADM2 inhibits FAK/AKT signaling, reducing HCC metastasis .